Duncker Streett & Co’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$598K Buy
24,821
+280
+1% +$7.32K 0.1% 151
2026
Q1
$689K Sell
24,541
-300
-1% -$7.99K 0.13% 136
2025
Q4
$619K Sell
24,841
-498
-2% -$12.6K 0.11% 132
2025
Q3
$646K Buy
25,339
+300
+1% +$7.41K 0.11% 128
2025
Q2
$607K Sell
25,039
-1,722
-6% -$40.2K 0.11% 136
2025
Q1
$678K Sell
26,761
-1,440
-5% -$37.7K 0.13% 127
2024
Q4
$748K Sell
28,201
-10,159
-26% -$276K 0.14% 117
2024
Q3
$1.11M Sell
38,360
-3,763
-9% -$110K 0.2% 103
2024
Q2
$1.18M Sell
42,123
-5,008
-11% -$138K 0.23% 97
2024
Q1
$1.31M Sell
47,131
-3,656
-7% -$101K 0.26% 91
2023
Q4
$1.46M Sell
50,787
-2,805
-5% -$84.8K 0.31% 83
2023
Q3
$1.78M Sell
53,592
-2,592
-5% -$91.7K 0.41% 68
2023
Q2
$2.06M Sell
56,184
-120
-0.2% -$4.67K 0.46% 65
2023
Q1
$2.3M Sell
56,304
-3,615
-6% -$156K 0.55% 56
2022
Q4
$3.07M Buy
59,919
+17
+0% +$815 0.74% 46
2022
Q3
$2.62M Sell
59,902
-1,039
-2% -$50.5K 0.68% 47
2022
Q2
$3.19M Buy
60,941
+19
+0% +$968 0.77% 41
2022
Q1
$3.15M Sell
60,922
-4,774
-7% -$248K 0.63% 46
2021
Q4
$3.88M Buy
65,696
+1,117
+2% +$55.3K 0.67% 43
2021
Q3
$2.78M Buy
64,579
+3,203
+5% +$142K 0.53% 63
2021
Q2
$2.4M Sell
61,376
-1,204
-2% -$46.8K 0.44% 77
2021
Q1
$2.27M Sell
62,580
-9,520
-13% -$338K 0.43% 79
2020
Q4
$2.65M Sell
72,100
-5,581
-7% -$205K 0.51% 62
2020
Q3
$2.71M Buy
77,681
+136
+0.2% +$4.77K 0.59% 54
2020
Q2
$2.41M Sell
77,545
-10,320
-12% -$351K 0.57% 59
2020
Q1
$2.72M Sell
87,865
-689
-0.8% -$23.5K 0.73% 45
2019
Q4
$3.29M Sell
88,554
-356
-0.4% -$12.7K 0.69% 49
2019
Q3
$3.03M Buy
88,910
+822
+0.9% +$29.9K 0.7% 45
2019
Q2
$3.62M Sell
88,088
-4,124
-4% -$164K 0.81% 31
2019
Q1
$3.72M Buy
92,212
+35
+0% +$1.4K 0.86% 28
2018
Q4
$3.82M Sell
92,177
-407
-0.4% -$16.9K 1.02% 17
2018
Q3
$3.87M Buy
92,584
+1,065
+1% +$41K 0.88% 22
2018
Q2
$3.15M Buy
91,519
+51
+0.1% +$1.74K 0.78% 31
2018
Q1
$3.08M Buy
91,468
+2,370
+3% +$81.5K 0.78% 29
2017
Q4
$3.06M Sell
89,098
-4,699
-5% -$160K 0.79% 29
2017
Q3
$3.18M Sell
93,797
-2,340
-2% -$75.2K 0.96% 23
2017
Q2
$3.06M Buy
96,137
+47
+0% +$1.48K 0.96% 27
2017
Q1
$3.12M Buy
96,090
+2,947
+3% +$92.9K 0.98% 24
2016
Q4
$2.87M Buy
93,143
+2,452
+3% +$74.9K 0.95% 25
2016
Q3
$2.91M Sell
90,691
-634
-0.7% -$21.2K 1.01% 22
2016
Q2
$3.05M Buy
91,325
+235
+0.3% +$7.5K 1.09% 21
2016
Q1
$2.56M Sell
91,090
-5,192
-5% -$148K 0.95% 29
2015
Q4
$2.95M Buy
96,282
+2,202
+2% +$69.3K 1.1% 19
2015
Q3
$2.8M Sell
94,080
-1,430
-1% -$45.9K 1.09% 20
2015
Q2
$3.04M Sell
95,510
-8,097
-8% -$264K 1.06% 19
2015
Q1
$3.42M Buy
103,607
+19
+0% +$604 1.12% 16
2014
Q4
$3.06M Sell
103,588
-42
-0% -$1.2K 1% 22
2014
Q3
$2.91M Sell
103,630
-3,142
-3% -$88.2K 0.99% 20
2014
Q2
$3.01M Buy
106,772
+3,234
+3% +$92.2K 0.97% 19
2014
Q1
$3.15M Buy
103,538
+21
+0% +$626 1.12% 14
2013
Q4
$3.01M Buy
103,517
+334
+0.3% +$9.72K 1.08% 14
2013
Q3
$2.81M Buy
103,183
+19
+0% +$517 1.14% 11
2013
Q2
$2.74M Buy
+103,164
New +$2.85M 1.05% 10

Other funds holding PFE

Duncker Streett & Co's PFE Position: Q2 2026 in Review

Duncker Streett & Co increased its Pfizer (PFE) stake by 1.1% in Q2 2026, buying an estimated $7.32K and bringing the position to 24,821 shares worth $598K. The position accounts for 0.1% of the portfolio, ranked #151.

Duncker Streett & Co first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.88M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Duncker Streett & Co held 24,821 shares of Pfizer worth $598K as of Q2 2026.
  • Duncker Streett & Co bought 280 Pfizer shares in Q2 2026, an estimated $7.32K.
  • Pfizer made up 0.1% of Duncker Streett & Co's portfolio in Q2 2026, its #151 holding.
  • Duncker Streett & Co first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Duncker Streett & Co's Pfizer position peaked at $3.88M in Q4 2021.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Duncker Streett & Co's 13F filing for Q2 2026, filed 28 Jul 2026.